About Ardelyx (ARDX)

Ardelyx Inc (ARDX) is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of cardio-renal and gastrointestinal diseases. The company's lead product candidate is tenapanor, a sodium/hydrogen exchanger 3 (NHE3) inhibitor, which is currently in Phase 3 clinical development for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis. Tenapanor works by reducing the absorption of dietary sodium and phosphate, resulting in increased bowel movements and decreased serum phosphorus levels. In addition to tenapanor, Ardelyx has a pipeline of potential drug candidates targeting other cardio-renal and gastrointestinal diseases.

In terms of stock price history, Ardelyx Inc (ARDX) has seen some volatility over the years. The stock had a 52-week high of $10.98 and a 52-week low of $0.75. It is important to note that past performance is not necessarily indicative of future results. Investors should always conduct thorough research and analysis before making any investment decisions. As of the most recent trading day, Ardelyx Inc (ARDX) had a market capitalization of $624.79 million. The PEG ratio, which is a measure of a stock's valuation in relation to its growth prospects, is -3.17 for Ardelyx Inc (ARDX). This indicates that the stock may be undervalued relative to its expected earnings growth. In terms of its industry, Ardelyx Inc (ARDX) operates in the biotechnology sector. The stock has performed better than the industry average. However, as with any investment, it is important to thoroughly research and analyze the company's financials, competitors, and industry trends before making any investment decisions.